This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bhatt-Mehta, V.
Right arrow Articles by Brenner, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bhatt-Mehta, V.
Right arrow Articles by Brenner, T.
Related Collections
Right arrow Therapeutics & Toxicology

PEDIATRICS Vol. 103 No. 4 April 1999, p. e48

ELECTRONIC ARTICLE:
Lack of Vancomycin-associated Nephrotoxicity in Newborn Infants: A Case-Control Study

Received Jul 27, 1998; accepted Nov 10, 1998.

Varsha Bhatt-Mehta*, Robert E. SchumacherDagger , Roger G. FaixDagger , Michelle Leady*, and Timothy Brenner§

From the * Department of Pharmacy and the College of Pharmacy and the Dagger  Department of Pediatrics and Communicable Diseases, University of Michigan Health Systems, Ann Arbor, Michigan; and the § Department of Pharmacy, University of Kentucky Medical Center, Lexington, Kentucky.

Objective.  The purpose of this study was to compare the incidence of nephrotoxicity, defined as doubling of baseline serum creatinine concentration, in newborn infants with peak vancomycin serum concentrations <= 40 µg/mL at steady state to infants with peak vancomycin serum concentrations >40 µg/mL. A secondary objective was to correlate concomitant disease states and potentially nephrotoxic drug therapy with rises in serum creatinine in vancomycin recipients.

Methods.  Newborn infants with culture-proven Staphylococcus aureus or coagulase-negative staphylococcal septicemia who received vancomycin therapy for >3 days between 1985 and 1995 were identified from an existing database and a review of medical record. All 69 patients included in the study had serial serum creatinine determinations, including a baseline value within 48 hours of starting treatment with vancomycin, and serum vancomycin concentrations determined after at least three doses, with peak and trough concentrations determined 1 hour after a 60-minute infusion and 15 to 30 minutes before a dose, respectively. Infants with congenital renal or cardiac anomalies were excluded. Demographic characteristics, vancomycin dosing regimen, serum vancomycin concentrations and sample times, concomitant drug therapy, and disease states were recorded. Patients were divided into group A (peak vancomycin concentration <= 40 µg/mL) and group B (peak vancomycin concentration >40 µg/mL). The change in serum creatinine concentration between the start and end of vancomycin therapy was determined. Nephrotoxicity was identified if serum creatinine doubled at any time from the start to the end of vancomycin therapy. Alternative definitions of nephrotoxicity (any rise in serum creatinine to >0.6 mg/dL or new abnormalities of urine sediment) were used in additional analyses.

Results.  A total of 69 evaluable patients (gestational age, 28.9 ± 3.0 weeks; birth weight, 1219 ± 516 g) were identified, 61 in group A and 8 in group B. Six patients in group A underwent doubling of serum creatinine concentration during vancomycin therapy, whereas none in group B did so. Serum creatinine doubled to >0.6 mg/dL in only 3 infants (all in group A). Any increase in serum creatinine to >0.6 mg/dL was seen in 10 infants, 9 of whom were in group A. No confounding variable, including previous or concomitant underlying disease states associated with renal dysfunction or treatment with other potentially nephrotoxic agents, were associated with a significant rise in serum creatinine.

Conclusion.  Vancomycin-associated nephrotoxicity is rare in neonates, even with serum peak concentrations >40 µg/mL.  Key words:  vancomycin, nephrotoxicity, newborn infants, NICU, Staphylococci, creatinine, renal, antibiotics.




This article has been cited by other articles:


Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
L Cataldi, R Leone, U Moretti, B De Mitri, V Fanos, L Ruggeri, G Sabatino, F Torcasio, V Zanardo, G Attardo, et al.
Potential risk factors for the development of acute renal failure in preterm newborn infants: a case-control study
Arch. Dis. Child. Fetal Neonatal Ed., November 1, 2005; 90(6): F514 - F519.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
W-H Tan, N Brown, A W Kelsall, and R J McClure
Dose regimen for vancomycin not needing serum peak levels?
Arch. Dis. Child. Fetal Neonatal Ed., November 1, 2002; 87(3): F214 - 216.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
A Narendra, M P White, H A Rolton, Z I Alloub, G Wilkinson, J H McColl, and J Beattie
Nephrocalcinosis in preterm babies
Arch. Dis. Child. Fetal Neonatal Ed., November 1, 2001; 85(3): F207 - 213.
[Abstract] [Full Text] [PDF]